Pityriasis rosea like eruption: A dermatological manifestation of
            <scp>Coronavac‐COVID</scp>
            ‐19 vaccine

Gökçek, Gözde Emel; Solak, Eda Öksüm; Çölgeçen, Emine

doi:10.1111/dth.15256

Cited by 5 publications

(5 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The vaccination types which preceded the pityriasis reactions were described as follows, listed from greatest to least incidence: 45 were Pfizer-BioNTech (47.9%), 11 , 12 ,14,18-20,22, 28-42 11 were Oxford-AstraZeneca (11.7%), 13 , 15 , 23-25 ,27, 43-45 8 were Moderna (8.5%) 10 , 12 ,21,26,46, 47 , 22 were Coronavac (23.4%), 16 , 17 , 41 , 48 , 49 2 were Sinopharm (2.1%), 50 2 were “COVID-19 vaccine by Beijing institute of biological products company” (2.1%), 51 1 Johnson & Johnson (1.1%), 52 1 was Covaxin (1.1%), 53 and two were listed as “unspecified mRNA” (2.1%). 54 , 55 …”

Section: Resultsmentioning

confidence: 99%

Pityriasis following COVID-19 vaccinations: a systematic review

Duzett,

Mercado,

Tasouli-Drakou

et al. 2023

Dermatol Reports

View full text Add to dashboard Cite

In the wake of a global COVID-19 pandemic, where innovations in vaccination technology and the speed of development and distribution have been unprecedented, a wide variety of post-vaccination cutaneous reactions have surfaced. However, there has not been a systematic review that investigates pityriasis eruptions and the associated variants following COVID-19 inoculations. A PubMed search using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) was performed to find case reports from the earliest record through November 2022. Data including types of vaccination and pityriasis were extracted and a quality review was performed. 47 reports with 94 patients were found: 64.9% had pityriasis rosea (PR), 3.2% PR-like eruptions, 16.0% pityriasis rubra pilaris (PRP), 7.4% pityriasis lichenoides et varioliformis acuta (PLEVA), 3.2% pityriasis lichenoides chronica (PLC), and 5.3% had reactions described as “atypical”. The top three COVID-19 vaccinations reported were Pfizer-BioNTech (47.9%), Oxford-AstraZeneca (11.7%), and Moderna (8.5%). Pityriasis reactivity was reported most frequently after the Pfizer-BioNTech vaccination, with pityriasis rosea being the most common variant. A large difference was additionally found between the ratio of post-vaccination pityriasis reactions following Pfizer and Moderna vaccinations (5.63), and the ratio of Pfizer’s usage in the United States as of December 28, 2022 relative to that of Moderna (1.59). Further studies with adequate follow-up periods and diagnostic testing will thus need to be performed to elucidate the root of this discrepancy and better characterize the association between different pityriasis reactions and COVID-19 vaccinations.

show abstract

Section: Resultsmentioning

confidence: 99%

Pityriasis following COVID-19 vaccinations: a systematic review

Duzett,

Mercado,

Tasouli-Drakou

et al. 2023

Dermatol Reports

View full text Add to dashboard Cite

show abstract

“…53 Significant triggers other than autoimmunity for PR can be bacterial, viral, environmental factors like seasonal change, atopy, stress, or drugs such as ACE inhibitors, like captopril, Allopurinol, hydrochlorothiazide, barbiturates, nimesulide, and metronidazole. 20,22 The drug-induced reaction is not commonly associated with HHV6/HHV7 reactivation. It mostly does not present with prodromal symptoms, herald patch, or eosinophilia under a microscope.…”

Section: Discussionmentioning

confidence: 99%

“…After individually screening the full‐text links, 31 studies were finalized that met the eligibility criteria and were used for data extraction and synthesis. 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 …”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Manifestation of pityriasis rosea and pityriasis rosea‐like eruptions after Covid‐19 vaccine: A systematic review

Khan

Hussein

Shareef

et al. 2023

Immunity Inflam & Disease

View full text Add to dashboard Cite

Background : After introducing Covid‐19 vaccines, a few side effects were reported, pityriasis rosea being one of them. Therefore, this study will systematically review its manifestation afteradministration. Methods : Databases were searched, covering a timeline from December 1, 2019 to February 28, 2022. Data were independently extracted and accessed for bias. SPSS statistical software version 25 was used for appropriate inferential statistics. Results : Thirty‐one studies were included for data extraction after screening following the eligibility criteria. A total of 111 people were identified to have developed pityriasis rosea or pityriasis rosea‐like eruptions after vaccination, out of which 36 (55.38%) were female. The average age of incidence was calculated to be 44.92 years, and 63 (62.37%) people presented after administration of the first dose. It was found popularly in the trunk area, either asymptomatically or with mild symptoms. Meantime the onset, was 8.58 days, and meantime it took to recover, was 6.44 weeks. Conclusion : The association between pityriasis rosea and pityriasis rosea‐like eruptions after Covid‐19 vaccines was established, but given the scarcity of studies, there is a need to conduct different clinical trials to confirm this association further and study the etiology and mechanism of the disease.

show abstract

“…21 Other skin manifestations encountered following COVID-19 vaccination include lichen planus, leukocytoclastic vasculitic rash, erythema multiforme-like rash, and pityriasis rosea-like rash. [22][23][24][25] The immune mechanisms of these manifestations remain unclear.…”

Section: B Amentioning

confidence: 99%